Last $2.99 USD
Change Today +0.09 / 3.10%
Volume 9.8K
RESX On Other Exchanges
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

restorgenex corp (RESX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/27/14 - $10.20
52 Week Low
03/5/14 - $2.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RESTORGENEX CORP (RESX)

Related News

No related news articles were found.

restorgenex corp (RESX) Related Businessweek News

No Related Businessweek News Found

restorgenex corp (RESX) Details

RestorGenex Corporation operates as a specialty biopharmaceutical company that focuses on developing products for dermatology, ophthalmology, and women’s health. Its product under development includes HYG-102, a soft estrogen for the treatment of aging skin fragility/thinning; HYG-440, a soft anti-androgen for the treatment of androgen excess, e.g. acne, male-pattern baldness, and hirsutism; and P529, a prescription dermatology compound used for the treatment of keloid scarring, psoriasis, atopic dermatitis, rosacea, actinic keratosis, Dupuytren’s disease, and the bullous blistering diseases. RestorGenex Corporation has Collaboration Agreement with Ferndale Pharma Group, Inc. for developing aging skin product. The company was formerly known as Stratus Media Group, Inc. and changed its name to RestorGenex Corporation in March 2014. RestorGenex Corporation is based in Los Angeles, California.

restorgenex corp (RESX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

restorgenex corp (RESX) Key Developments

U.S. Food and Drug Administration Grants RestorGenex Corporation's Orphan Drug Designation for Res-529 for Treatment of Glioblastoma Multiforme

RestorGenex Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for RES-529 for the treatment of glioblastoma multiforme. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the United States. Orphan drug designation qualifies the sponsor of the product for a tax credit and seven years of marketing exclusivity. RES-529 is a first-in-class inhibitor of the PI3K/Akt/mTOR pathway. Signaling components of the PI3K pathway are central regulators of cell proliferation, growth, differentiation, survival and angiogenesis. Up to 80% of tumor types have been shown to have an aberrant up-regulation of the PI3K pathway. Activation of this pathway has been observed in glioblastoma patients thus making PI3K pathway inhibition a validated target for therapeutic intervention in glioblastoma multiforme. RES-529 was developed from a non-steroidal, small molecule drug library through computational design, synthetic and medicinal chemistry. RES-529 is the result of three generations of design work. Through a series of in vitro and in vivo animal models, RES-529 has been shown to have activity in several cancer types due to its ability to target and inhibit the PI3K/Akt/mTOR signal transduction pathway, specifically as a first-in-class allosteric, dissociative inhibitor of both TORC1 and TORC2.

RestorGenex Announces Presentation of Scientific Data on RES-529 for the Treatment of Glioblastoma at Keystone Symposia on PI 3-Kinase Signaling Pathways

RestorGenex Corporation announced that it presented scientific data on RES-529 for the treatment of glioblastoma multiforme (GBM) at the Keystone Symposia Series on PI 3-Kinase (PI3K) Signaling Pathways. The presentation titled "Validation of RES-529, a novel TORC1/TORC2 allosteric dissociative PI3K inhibitor in glioblastoma multiforme" was presented on January 16, 2015. RES-529 is a proprietary first-in-class PI3K/Akt/mTOR pathway inhibitor that is capable of dissociating both TORC1 and TORC2. poster presentation discussed in vitro and in vivo data from preclinical studies evaluating RES-529 in GBM, a disease in which elevated expression of the PI3K is commonly seen. In the first study, RES-529 demonstrated an ability to inhibit signal transducers of the PI3K pathway that are controlled by TORC1 and TORC2. This mechanism was shown in a variety of tumor cells, including cells that have lost tumor suppressor PTEN. In a second study, RES-529 was compared with two catalytic inhibitors of the PI3K pathway currently in the clinic; a combination PI3K/mTOR agent and a combination PI3K/Akt agent. In these experiments, RES-529 showed a 20 to more than 100 fold increase in activity above the other inhibitors. In addition, RES-529 was shown to inhibit tumor cell survival up to two orders of magnitude over that of a rapamycin analog PI3K inhibitor (TORC1 dissociative inhibitor approved by the FDA for select tumor types), in a tumor cell model known to show resistance to TORC1 inhibition. A third study was presented that demonstrated RES-529 penetrates the blood-brain barrier. This was supported by efficacy data of RES-529 in an orthotopic GBM xenograft model where RES-529 showed an improvement in survival vs. control, similar to radiation treatment. When utilized in combination with radiation, RES-529 showed synergy extending survival above that of either RES-529 or radiation alone.

Restorgenex Corporation Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 10:00 AM

Restorgenex Corporation Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 10:00 AM. Venue: Club Med, Sandpiper Bay, Florida, United States. Speakers: Stephen M. Simes, Chief Executive Officer and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RESX:US $2.99 USD +0.09

RESX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RESX.
View Industry Companies

Industry Analysis


Industry Average

Valuation RESX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 778.9x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 441.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESTORGENEX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at